EGFR and neoplasm: To characterize the role of NANOG in the acquisition of cisplatin resistance by autophagy-mediated EGFR activation in cisplatin-resistant tumor cells, we first assessed the expression of NANOG in CaSki cells at different rounds of in vivo selection by cisplatin (CaSki P to CR) and found a stepwise increase in NANOG expression from CaSki P to CR (Fig. 3a).